Novartis And HGS Close The Door On Zalbin
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
You may also be interested in...
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.